Introduction
critically ill, hyperpermeability, vascular leak, pulmonary edema, ARDS, Critically ill, gastrointestinal dysfunction, intestinal edema
CORONAVIRUS DISEASE 2019, CRITICALLY ILL, PULMONARY EDEMA, CRITICALLY ILL, SECONDARY, GASTROINTESTINAL DYSFUNCTION, ARDS, ACUTE RESPIRATORY DISTRESS SYNDROME, DELAYED GASTRIC EMPTYING
Coronavirus disease 2019 (COVID-19) can lead to the development of acute respiratory distress syndrome (ARDS) [The tyrosine kinase inhibitor imatinib attenuates vascular hyperpermeability and pulmonary edema in various preclinical in vitro and animal models of vascular leak [Clinical benefits of imatinib were predominantly observed in patients admitted to the intensive care unit (ICU). In a secondary analysis of the CounterCOVID trial, patients were characterized using plasma biomarkers for hierarchical clustering [In this trial, a newly developed intravenous (IV) formulation was used to bypass gastrointestinal dysfunction often observed in critically ill patients. Critically ill patients often suffer from gastrointestinal dysfunction, which includes delayed gastric emptying and intestinal edema, which may delay drug uptake and drug exposure [The InventCOVID trial evaluated the efficacy and safety of IV imatinib in patients receiving invasive ventilation for moderate-to-severe COVID-19 ARDS. We hypothesized that IV imatinib would stabilize the alveolocapillary barrier and thereby reduce pulmonary edema, quantified by extravascular lung water index (EVLWi), a validated measure of pulmonary edema [